WSC 2023 | Anti-inflammatory agents for the treatment of stroke

Inflammatory responses can catalyze tissue death and worsen clinical outcomes for stroke patients. Aristeidis Katsanos, MD, PhD, McMaster University, Hamilton, Ontario, Canada, discusses current drug molecules under evaluation for their potential to modulate inflammation to improve clinical outcomes following stroke. ACTION (NCT04834388) investigated the efficacy of interleukin-1 inhibitor anakinra to reduce secondary brain damage after spontaneous hemorrhagic stroke. ACTION II (NCT02730455) assessed the clinical effect of natalizumab in patients who had suffered acute ischemic stroke. There are ongoing studies assessing fingolimod, a treatment currently used in multiple sclerosis, for patients with both acute ischemic stroke and intracerebral hemorrhage. Colchicine is another key molecule under investigation, with the results of CHANCE-3 (NCT05439356) having been presented at WSC 2023. Dr Katsanos predicts anti-inflammatory treatment for stroke will see more attention in the coming years. This interview took place at the World Stroke Congress (WSC) 2023 in Toronto, Canada.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.